Supplemental material for JAAD publication titled: Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate to severe plaque psoriasis: 24 Week results from a Phase III open-label, randomized, multicenter study

Published: 12-11-2020| Version 3 | DOI: 10.17632/vn3spwfg52.3
Contributor:
Nina Magnolo

Description

Supplemental material for JAAD publication titled: "Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate to severe plaque psoriasis: 24 Week results from a Phase III open-label, randomized, multicenter study" to be published in Journal of the American Academy of Dermatology

Files